Close
CDMO Safety Testing 2026
Novotech

Visiongain predicts boom in pharma contract manufacturing market

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...
- Advertisement -

The global contract manufacturing will reach $64.07bn in 2016, according to a new report by London-based business information company Visiongain. The report, ‘Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021,’ says that the market will grow with a CAGR of 8.7% between 2010 and 2016, with finished dosage forms manufacturing driving the revenue growth. API manufacturing remained the largest market sector in 2010, accounting for 71.1% of the total market and the API manufacturers in India and China will achieve increasing demand for their services.Between 2011 and 2021, demand for contract manufacturing services will continue to come from developed market-based pharmaceutical companies, the Visiongain report says.

This decade, pharmaceutical companies will outsource increasing amounts of manufacturing, as companies focus on activities such as R&D and marketing. Growth in the biotechnology market will also provide a great opportunity for contract manufacturing organisations.

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป